Tag: chronic pruritus therapeutics market trends report

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic pruritus therapeutics market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Chronic Pruritus Therapeutics Market expected to grow between 2026 and 2030?

The chronic pruritus therapeutics market size has shown robust expansion in recent years. It is anticipated to increase from $10.91 billion in 2025 to $11.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. This historical growth can be linked to the rising prevalence of chronic dermatological conditions, more widespread application of topical corticosteroids, enhanced diagnostic differentiation of pruritus causes, an uptick in dermatology specialist consultations, and the broadened availability of antihistamine therapies.

The chronic pruritus therapeutics market is anticipated to experience substantial growth over the upcoming years, projected to reach a size of $15.33 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.0%. This expansion during the forecast period is attributable to several factors, including a rise in biologic drug approvals, increased investment in dermatology research pipelines, an intensifying focus on immune-mediated itch mechanisms, wider online pharmacy access, and a growing patient demand for enduring relief solutions. Key trends foreseen for this period encompass a greater adoption of targeted biologic therapies, an increasing emphasis on personalized pruritus treatment strategies, the ongoing development of innovative anti-itch molecules, broader implementation of combination therapy protocols, and a heightened focus on managing symptoms over the long term.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Drivers Are Influencing Market Acceleration In The Chronic Pruritus Therapeutics Market?

The escalating healthcare expenditure is anticipated to drive the expansion of the chronic pruritus therapeutics market moving forward. This expenditure represents the total financial outlay by individuals, organizations, or governments for the prevention, treatment, and management of various health conditions. Its increase stems from advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies frequently involve higher costs, thus raising overall healthcare spending. Growing healthcare expenditure benefits chronic pruritus therapeutics by enhancing patient access to dermatology care, facilitating the adoption of advanced treatment options, and stimulating further investment in innovative therapies. As an illustration, in December 2024, the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, reported that in 2023, U.S. health care expenditures saw a 7.5% increase, reaching $4.9 trillion, equivalent to approximately $14,570 per individual. Hence, the increasing healthcare expenditure is fueling the growth of the chronic pruritus therapeutics market.

What Leading Segments Are Studied In The Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Which Trends Are Expected To Influence The Chronic Pruritus Therapeutics Market In The Upcoming Years?

Major companies operating in the chronic pruritus therapeutics market are focusing on developing innovative formulations, such as intravenous (IV) injection, to enhance treatment efficacy and provide faster relief for patients. Intravenous (IV) injection aids in treating pruritus by delivering medications, including antihistamines or corticosteroids, directly into the bloodstream to rapidly alleviate itching and reduce inflammation. For instance, in September 2023, Cara Therapeutics Inc., a US-based company manufacturing therapeutics, announced that its partner company Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received approval for Korsuva IV injection syringe, a treatment for pruritus in hemodialysis patients, from the Japan’s Ministry of Health, Labour and Welfare, a Japan-based government agency. This approval stemmed from positive Phase 3 clinical trial results carried out by Maruishi in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment displayed significant improvements in itching scores compared to a placebo and was well-tolerated by patients. The approval also triggers a $1.5 million milestone payment to Cara Therapeutics, the developer of Korsuva, as per the terms of their licensing agreement with Maruishi.

Which Major Industry Participants Are Leading The Chronic Pruritus Therapeutics Market Growth?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Cipla Limited, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Region Is Projected To Lead The Chronic Pruritus Therapeutics Market During The Forecast Period?

North America was the largest region in the chronic pruritus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Pruritus Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2026, By The Business Research Company

Drugs For Benign Prostatic Hypertrophy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Gout Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Projected Valuation Of The Chronic Pruritus Therapeutics Market In The Coming Years?

In recent times, the market size of chronic pruritus therapeutics has seen robust growth. It is projected to expand from $10.17 billion in 2024 to $10.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. The historical growth trend can be ascribed to factors such as a surge in chronic pruritus incidence, escalating demand for efficient therapies, an uptick in regulatory consents, augmented product clearances, and a rise in mergers, collaborations, and acquisitions among industry players.

The market size for chronic pruritus therapeutics is predicted to experience substantial growth in the coming years, reaching $14.36 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%. The expected growth during this forecast period can be credited to factors such as increasing awareness, a rise in atopic dermatitis cases, heightened emphasis on personalized medicine, a surge in dermatological condition prevalence, and an expanding patient population. Key trends anticipated for this period encompass the launch of ground-breaking medicines, the manufacturing of unique biologics and targeted treatments, progression in technology, the introduction of state-of-the-art drug delivery systems, partnerships between pharmaceutical corporations and research organizations, and the advent of digital health technologies such as telemedicine.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Market Dynamics Are Playing A Critical Role In The Growth Of The Chronic Pruritus Therapeutics Market?

The increase in cases of atopic dermatitis is believed to drive the expansion of the chronic pruritus therapeutics market. Characterized by dryness, redness, irritation, and itching, atopic dermatitis (AD) is a persistent skin inflammation often seen in individuals with a familial history of allergies, asthma, or hay fever. This increase is linked to several factors such as inherited susceptibility, changes in the environment, lifestyle habits, the hygiene hypothesis, higher exposure to allergens, and imbalances in skin microbiome. Chronic pruritus therapeutics help to alleviate the continuous itching related to atopic dermatitis by focusing on the root inflammatory pathways, decreasing skin irritation, and enhancing patient comfort. For instance, as stated by the International Eczema Council, a nonprofit organization based in the U.S. in 2022, roughly 223 million people around the world had atopic dermatitis (GBD 2022). This included about 43 million children between the ages 1-4, underlining the disease’s high occurrence in early years of life. Hence, the growing cases of atopic dermatitis are fueling the expansion of the chronic pruritus therapeutics market.

Which Sub-Segments Are Driving Growth Within The Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeuticsmarket covered in this report is segmented –

1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types

2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types

3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies

What Future-Focused Trends Are Anticipated In The Chronic Pruritus Therapeutics Market?

Prominent firms engaged in the chronic pruritus therapeutics sector are directing their efforts towards the creation of novel formulations, such as intravenous (IV) injections, to improve treatment’s effectiveness and provide rapid relief to patients. Antihistamines or corticosteroids can be directly administered into the bloodstream using IV injections, providing immediate relief from itching and reducing inflammation. For instance, in September 2023, Cara Therapeutics Inc., an American therapeutics manufacturer, announced that its partner firm, Maruishi Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, obtained approval from Japan’s Ministry of Health, Labour and Welfare for the Korsuva IV injection syringe. This formulation, intended to treat pruritus in hemodialysis patients, received approval based on the positive results from a Phase 3 clinical trial conducted in collaboration with Kissei Pharmaceutical Co., Ltd. The trial results highlighted significant reductions in itchiness when compared to a placebo and showed good patient tolerance. Furthermore, the approval activates a milestone payment of $1.5 million to Cara Therapeutics, the original developer of Korsuva, per their licensing terms with Maruishi.

Which Players Are Shaping The Competitive Landscape Of The Chronic Pruritus Therapeutics Market?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

How Do Regional Dynamics Influence The Chronic Pruritus Therapeutics Market Performance?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Chronic Pruritus Therapeutics Market Size Likely To Evolve From 2025 Through 2034?

The chronic pruritus therapeutics market has witnessed substantial growth in recent years. It is anticipated to expand from $10.17 billion in 2024 to $10.91 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.3%. The growth observed in prior periods stems from factors such as the rising incidence of chronic pruritus, an increasing need for effective treatments, a growing number of regulatory approvals, an increase in product approvals, and a rise in mergers, collaborations, and acquisitions among industry participants.

The chronic pruritus therapeutics market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $14.36 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is driven by factors such as increasing awareness, a rise in atopic dermatitis cases, a growing emphasis on personalized medicine, the expanding prevalence of dermatological conditions, and an expanding patient demographic. Key trends defining this period encompass the introduction of new innovative medicines, the progress in developing novel biologics and targeted therapies, ongoing technological advancements, the incorporation of advanced drug delivery systems, strategic collaborations between pharmaceutical companies and research institutions, and the utilization of digital health technologies, including telemedicine.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Drivers Are Supporting Growth Of The Chronic Pruritus Therapeutics Market?

The increasing incidence of atopic dermatitis is anticipated to propel the expansion of the chronic pruritus therapeutics market going forward. Atopic dermatitis (AD) is a persistent inflammatory skin disorder characterized by redness, itching, dryness, and irritation, frequently affecting individuals with a familial background of allergies, asthma, or hay fever. The growing occurrence of atopic dermatitis can be attributed to multiple factors, such as genetic susceptibility, environmental shifts, lifestyle habits, the hygiene hypothesis, heightened exposure to allergens, and imbalances in the skin microbiome. Chronic pruritus therapeutics effectively alleviates the persistent itching associated with atopic dermatitis by targeting underlying inflammatory pathways, thus reducing skin irritation and improving patient comfort. For instance, in 2022, according to the International Eczema Council, a US-based nonprofit organization, approximately 223 million people globally were living with atopic dermatitis (GBD 2022), including 43 million children aged 1-4, which underscores the condition’s significant prevalence in early childhood. Hence, the rising prevalence of atopic dermatitis is driving the growth of the chronic pruritus therapeutics market.

What Are The Major Segments Identified In The Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeuticsmarket covered in this report is segmented –

1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types

2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types

3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies

What Key Innovation Trends Are Fueling Advancements In The Chronic Pruritus Therapeutics Market?

Key companies operating within the chronic pruritus therapeutics market are concentrating on developing innovative formulations, such as intravenous (IV) injections, to enhance treatment effectiveness and provide patients with faster relief. IV injections aid in treating pruritus by directly delivering medications, like antihistamines or corticosteroids, into the bloodstream to rapidly alleviate itching and reduce inflammation. For example, in September 2023, Cara Therapeutics Inc., a US-based company specializing in therapeutics, announced that its partner, Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, obtained approval from the Japan’s Ministry of Health, Labour and Welfare, a Japan-based government agency, for Korsuva IV injection syringe, designed to treat pruritus in hemodialysis patients. This authorization was granted following positive Phase 3 clinical trial results, which Maruishi conducted in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment exhibited significant improvements in itching scores compared to a placebo and was well-tolerated by patients. Moreover, this approval triggers a $1.5 million milestone payment to Cara Therapeutics, the originator of Korsuva, as per the terms of their licensing agreement with Maruishi.

Which Global Market Leaders Are Shaping The Future Of The Chronic Pruritus Therapeutics Sector?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Region Is Projected To Lead The Chronic Pruritus Therapeutics Market During The Forecast Period?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Chronic Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company

Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report

Chronic Cough Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report

Late Stage Chronic Kidney Disease Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Chronic Pruritus Therapeutics Market Growth Performance Trended Historically, And What Lies Ahead?

In the past few years, the chronic pruritus therapeutics market has seen robust growth. The market size is projected to increase from $10.17 billion in 2024 to $10.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. The historic growth can be credited to factors such as heightened instances of chronic pruritus, a surge in the need for viable treatments, an uptick in regulatory approvals, an increase in approved products, and a rise in mergers, partnerships, and takeovers among industry players.

In the next few years, the chronic pruritus therapeutics market is slated to experience robust growth, reaching a value of $14.36 billion in 2029, with a CAGR of 7.1%. The growth during the projected period can be linked to multiple factors such as the increase in awareness, prevalence of atopic dermatitis, a growing emphasis on personalized medication, the rise in dermatological conditions, and an expanding patient population. The forecast period also foresees major trends like the launch of innovative drugs, the creation of unique biologics and targeted treatments, advancements in technology, the integration of sophisticated drug delivery systems, partnerships between pharma companies and research bodies, and the advent of digital health solutions such as telemedicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

What Are the Core Market Drivers Propelling Growth in the Chronic Pruritus Therapeutics Industry?

The growth of the chronic pruritus therapeutics market is anticipated to be driven by the increasing instances of atopic dermatitis. Characterized by redness, itching, dryness, and irritation, atopic dermatitis (AD) is a persistent skin condition caused by chronic inflammation, primarily affecting individuals with a familial history of allergies, asthma, or hay fever. Various factors, such as genetic predisposition, environmental alterations, lifestyle elements, the hygiene theory, heightened allergen exposure, and imbalances in the skin microbiome, contribute to the escalating prevalence of atopic dermatitis. Chronic pruritus therapeutics plays a crucial role in managing the continuous itchiness associated with AD by focusing on the fundamental inflammatory pathways, decreasing skin irritation, and enhancing patient comfort. For example, in 2022, the International Eczema Council, a nonprofit organization based in the US, reported that approximately 223 million people worldwide were afflicted with atopic dermatitis (GBD 2022), including 43 million children between the ages of 1-4, underlining the significant occurrence of this condition in early childhood. As a result, the escalating number of atopic dermatitis cases is fuelling the growth of the chronic pruritus therapeutics market.

How Is the Chronic Pruritus Therapeutics Market Segmented?

The chronic pruritus therapeuticsmarket covered in this report is segmented –

1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types

2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types

3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Which Regions Are Driving the Next Phase of the Chronic Pruritus Therapeutics Market Growth?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Chronic Pruritus Therapeutics Industry?

Leading companies in the chronic pruritus therapeutics market are channeling their efforts into creating novel formulations, such as intravenous (IV) injections, to improve treatment effectiveness and speed up patient relief. IV injection is a proven method in pruritus treatment, allowing for direct delivery of drugs like antihistamines or corticosteroids into the patient’s circulation to rapidly ease itchiness and lessen inflammation. For example, in September 2023, a US firm known as Cara Therapeutics Inc. which engages in producing therapeutics, announced their associate company, Maruishi Pharmaceutical Co. Ltd, a pharmaceutical enterprise originating from Japan, has secured approval for Korsuva IV injection syringe, a pruritus treatment for hemodialysis patients, from the Japan’s Ministry of Health, Labour and Welfare, a government agency in Japan. This approval was cemented on the back of successful Phase 3 clinical trial results orchestrated by Maruishi alongside Kissei Pharmaceutical Co., Ltd. The treatment demonstrated substantial enhancements in itchiness ratings when compared to a placebo and patients tolerated it well. As a result of this approval, a $1.5 million milestone payment is due to Cara Therapeutics, the creator of Korsuva, in line with their licensing agreement with Maruishi.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

How Is the Chronic Pruritus Therapeutics Market Defined and What Are Its Core Parameters?

Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Chronic Pruritus Therapeutics Market from 2024 to 2025?

The market size for treatments of chronic pruritus has seen substantial growth in recent years. The market is projected to increase from $10.17 billion in 2024 to $10.94 billion in 2025, with a compound annual growth rate (CAGR) of 7.6%. The expansion during the historical period is due to factors such as an increased incidence of chronic pruritus, growing need for efficacious treatments, more regulatory approvals, an uptick in product clearances, and an escalation in the incidence of mergers, collaborations, and acquisitions among industry players.

What Is the Projected Market Size of the Chronic Pruritus Therapeutics Market?

In the ensuing years, the market size for chronic pruritus therapeutics is anticipated to witness robust expansion. The market prediction is a growth to $14.49 billion by 2029, with a compound annual growth rate (CAGR) of 7.3%. The forecasted growth period is linked to increased awareness, surge in atopic dermatitis cases, emphasis on personal medicine, higher occurrence of dermatological conditions, and expanding patient population. The forecast period is also expected to see major trends such as the introduction of pioneering medicines, creation of ground-breaking biologics and targeted therapies, technological enhancements, assimilation of cutting-edge drug delivery systems, partnerships between pharmaceutical organizations and research institutions, as well as the emergence of digital health technologies like telemedicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Who are the Major Competitors in the Chronic Pruritus Therapeutics Market Outlook?

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

What Is Fueling Growth in the Chronic Pruritus Therapeutics Market?

The growing incidence of atopic dermatitis is anticipated to fuel the growth of the chronic pruritus therapeutics market in the future. Atopic dermatitis (AD) is a long-term inflammatory skin disease characterized by symptoms including redness, dryness, and itchiness, typically impacting individuals who have a family history of allergies, hay fever, or asthma. The cause of increasing cases of atopic dermatitis can lay blame on factors like genetic predisposition, lifestyle changes, alterations in the environment, the hygiene hypothesis, overexposure to allergens, and imbalances in the skin microbiome. Chronic pruritus therapeutics are designed to ease the continuous itchiness associated with atopic dermatitis by focusing on inflammatory pathways, reducing skin inflammation and improving patient comfort. For example, the International Eczema Council, a nonprofit organization based in the US, estimated that in 2022, approximately 223 million people worldwide were suffering from atopic dermatitis (GBD 2022), which includes 43 million children between the ages of 1-4, highlighting the substantial incidence of this condition in early childhood. As such, the increasing occurrence of atopic dermatitis is cited as a key driver in the expansion of the chronic pruritus therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Which Chronic Pruritus Therapeutics Market Segments Are Growing the Fastest?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Which Industry Trends Are Shaping the Future of the Chronic Pruritus Therapeutics Market?

Leading corporations in the chronic pruritus therapeutics market are centering their efforts on the creation of novel formulations such as the intravenous (IV) injection to augment the effectiveness of treatments and provide quick relief to patients. The use of IV injection in pruritus treatment allows for antihistamines or corticosteroids to be directly injected into the bloodstream, swiftly relieving itching and reducing inflammation. An example of this is when Cara Therapeutics Inc., a US-based therapeutics manufacturer, announced in September 2023 that its partner, Maruishi Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, gained approval from Japan’s Ministry of Health, Labour and Welfare for its Korsuva IV injection syringe. This treatment for pruritus in hemodialysis patients was approved following the positive outcome of a Phase 3 clinical trial led by Maruishi in partnership with Kissei Pharmaceutical Co., Ltd. The application demonstrated a considerable enhancement in itching scores in comparison to a placebo and was generally well-received by patients. According to the licensing agreement with Maruishi, Cara Therapeutics, the creator of Korsuva, will receive a milestone payment of $1.5 million following this approval.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

Which Countries Are Leading the Chronic Pruritus Therapeutics Market?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

This Report Delivers Insight On:

1. How big is the chronic pruritus therapeutics market, and how is it changing globally?

2. Who are the major companies in the chronic pruritus therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the chronic pruritus therapeutics market right now?

4. Which products or customer segments are growing the most in the chronic pruritus therapeutics market?

5. What factors are helping or slowing down the growth of the chronic pruritus therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the Anticipated CAGR of the Chronic Pruritus Therapeutics Market, and What Factors Will Drive It?

Over the past few years, the market size for chronic pruritus therapeutics has seen robust growth. It is projected to escalate from $10.17 billion in 2024 to $10.94 billion in 2025, sustaining a compound annual growth rate (CAGR) of 7.6%. This previous period’s growth can be credited to an increasing incidence of chronic pruritus, a rising need for successful treatments, growing regulatory acceptance, a surge in product approvals, and a rise in mergers, collaborations, and acquisitions among industry players.

The market size for chronic pruritus therapeutics is anticipated to witness considerable expansion in the coming years. The projected growth indicates a likelihood of reaching $14.49 billion by 2029, boasting a compound annual growth rate (CAGR) of 7.3%. The expected growth during this forecast period is linked to increased awareness, a surge in atopic dermatitis, a heightened emphasis on personalized medicine, a rising occurrence of skin disorders, and an expanding patient pool. Notable trends predicted for this forecast period encompass the introduction of unique medicines, the production of ground-breaking biologics and targeted therapies, advancements in technology, the incorporation of improved drug delivery systems, as well as collaborative efforts between pharmaceutical companies and research institutions, and the growth of digital health technologies such as telemedicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market’s growth is expected to surge forward due to the increasing occurrence of atopic dermatitis. Atopic dermatitis, or AD, is renowned for its chronic inflammation of the skin, with symptoms such as redness, dryness, itching, and irritation, typically affecting those with a family history of allergies, asthma, or hay fever. The heightened presence of atopic dermatitis is linked to a mix of factors such as genetic predisposition, alterations to the environment, lifestyle changes, the hygiene hypothesis, increased exposure to allergens, and imbalances in the skin’s microbiome. Therapies for chronic pruritus provide relief from the relentless itching affiliated with atopic dermatitis by focusing on the inflammatory pathways beneath the surface, limiting skin irritation, and enhancing patient comfort. For example, the International Eczema Council, a nonprofit organization based in the US, reported that in 2022, around 223 million people worldwide (GBD 2022), including 43 million children aged between 1-4, suffered from atopic dermatitis. This underscores the condition’s tremendous early childhood prevalence. Hence, the burgeoning presence of atopic dermatitis is propelling the chronic pruritus therapeutics market’s growth.

Which Key Market Segments Comprise the Chronic Pruritus Therapeutics Market and Drive Its Revenue Growth?

The chronic pruritus therapeutics market covered in this report is segmented –

1) By Product Type: Corticosteroid, Antihistamine, Local Anesthetic, Counterirritant, Immunosuppressant, Calcineurin Inhibitors, Other Product Types

2) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Other Disease Types

3) By Distribution Channel: Hospital Pharmacies, Drug stores And Retail Pharmacies, Online Providers

Subsegments:

1) By Corticosteroid: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids

2) By Antihistamine: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetic: Topical Local Anesthetics, Injectable Local Anesthetics

4) By Counterirritant: Menthol-Based Counterirritants, Camphor-Based Counterirritants

5) By Immunosuppressant: Systemic Immunosuppressants, Topical Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy, Pimecrolimus-Based Therapy

7) By Other Product Types: Biologic Therapies, Emerging Novel Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp

Which Areas Are Leading Regions in the Chronic Pruritus Therapeutics Market Expansion Across the Globe?

North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theChronic Pruritus Therapeutics Market Over the Coming Years?

Leading enterprises within the sector of chronic pruritus therapeutics are concentrating on creating novel formulations, including intravenous (IV) injections, in a bid to boost treatment effectiveness and expedite patient relief. The use of IV injections is beneficial in pruritus treatment as they deliver drugs like antihistamines or corticosteroids instantly into the bloodstream to relieve itching and diminish inflammation. As an exemplification, Cara Therapeutics Inc., a firm situated in the US that produces therapeutics, revealed in September 2023 that its collaborator, Maruishi Pharmaceutical Co. Ltd., a Japanese pharmaceutical firm, obtained the endorsement for the Korsuva IV injection syringe from Japan’s Ministry of Health, Labour and Welfare. This pruritus treatment for hemodialysis patients was given approval based on favorable outcomes from a Phase 3 clinical trial by Maruishi in alliance with Kissei Pharmaceutical Co. Ltd. The treatment demonstrated considerable enhancements in itching scores in comparison to a placebo, and was well-received by patients. The validation also activated a $1.5 million milestone remittance to Korsuva’s creator, Cara Therapeutics, under the stipulations of its licensing contract with Maruishi.

View the full report here:

https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report

How Is the Chronic Pruritus Therapeutics Market Conceptually Defined?

Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21147

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model